Lung cancer case study and clinical trial

Share This Post

1. Diagnosis and first treatment of lung cancer

Patient Lu was diagnosed with lung adenocarcinoma and lymph node metastasis on August 26, 2005. A left lower lobectomy was performed on September 22, 2005. Carboplatin combined with taxotere was used 4 times after surgery. On August 3, 2007, due to pleural effusion, the diagnosis was confirmed to be recurring, and she was treated with Tarceva (the number of cycles is unknown). On January 8, 2008, the cancer progress was found on the reexamination, and then Tarceva treatment was stopped and Libita treatment was started for 16 cycles. At the same time, vertebral hip metastasis was found and 4 cycles of Zetai were performed.

2. The first time to participate in clinical trials, the condition is under control.

In July 2010, Mr. Lu reexamined a large area of ​​brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumor was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.

3. In the second clinical trial, the tumor disappeared obviously.

On August 6, 2012, Mr. Lu participated in the AP26113 drug clinical trial at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the tumor in the brain decreased and became large.

4. Discover rare gene mutations and look forward to participating in new clinical trials

Re-examination in July 2014, whole-body PET showed: Brain lesions were basically stable, and chest had obvious progress. On May 12, 2014, the suspected anti-AP26113 lymph (3 cells, biggest 1.1 cm) cultured cell lines were performed at Massachusetts General Hospital and continued to take AP26113.

In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastoma and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.

On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunotherapy phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

CAR T Cell therapy for AIDS related B Cell malignancies
Aids cancer

CAR T Cell therapy for AIDS related B-Cell malignancies

CAR T cell therapy for HIV-related B cell malignancies involves genetically modifying a patient’s T cells to express chimeric antigen receptors (CARs) targeting CD19 on B cells. This treatment holds promise in eradicating malignant B cells but must carefully manage immunosuppression in HIV-positive individuals.

Cancer statistics in India 2024
Cancer

Cancer statistics in India 2024: Incidence, estimates and projections

In 2024, cancer will remain a significant health challenge in India. The country sees over 1.5 million new cases a year. Breast and oral cancers are most prevalent among women and men, respectively. Sadly, many cases are diagnosed late, impacting survival rates. Improved awareness and access to healthcare are crucial. By 2030, cancer incidence is expected to surpass 1.7 million cases annually. Efforts to enhance prevention, early detection, and treatment access are crucial to mitigate this growing burden. Check our cancer statistics in India for 2024 and future projections.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
Need help with cancer treatment?
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy